Does HPV Vaccination Lower Cancer Risk in Males? - Scorecard - MDSpire

Does HPV Vaccination Lower Cancer Risk in Males?

A large real-world study found a lower incidence of any HPV-related cancer among vaccinated males

  • By

  • Kerri Miller

  • April 17, 2026

  • 3 min

Share

Clinical Scorecard: Does HPV Vaccination Lower Cancer Risk in Males?

At a Glance

CategoryDetail
ConditionHPV-related cancers in males
Key Mechanisms9-valent HPV vaccine reduces cancer incidence
Target PopulationMales aged 9 to 26 years
Care SettingHealth care centers in the US

Key Highlights

  • Lower incidence of HPV-related cancers in vaccinated males compared to unvaccinated peers
  • Hazard ratio of 0.54 indicates a 46% lower risk of HPV-related cancer
  • Study included over 615,000 vaccinated and 2.3 million unvaccinated males
  • Findings support expanding sex-neutral HPV vaccination programs
  • Results primarily driven by head and neck cancer diagnoses

Guideline-Based Recommendations

Diagnosis

  • Cancer diagnoses based on administrative coding; caution due to potential misclassification

Management

  • Encourage HPV vaccination in males aged 9 to 26 years

Monitoring & Follow-up

  • Monitor cancer incidence and vaccination rates in targeted populations

Risks

  • Limitations include unaccounted risk factors and potential misclassification of vaccination status

Patient & Prescribing Data

Males aged 9 to 26 years

9-valent HPV vaccine is effective in reducing cancer risk

Clinical Best Practices

  • Administer HPV vaccines to both males and females
  • Promote awareness of HPV vaccination benefits in young males
  • Integrate HPV vaccination into routine adolescent health care

Related Resources & Content

Original Source(s)

Does HPV Vaccination Lower Cancer Risk in Males?

  • by Kerri Miller

  • April 17, 2026

Related Content

How Does Social Media Influence Health Decisions?

National survey findings suggest many US adults report making health decisions based on social media despite widespread concerns about the accuracy of health information shared to the platforms.

Joint Site May Influence RA Treatment Response

A Swiss registry study found that the wrist and second and third metacarpophalangeal joints consistently resolved more slowly than most other joints following biologic or targeted synthetic therapy.

FDA Expands Bladder Cancer Regimen

KEYNOTE-B15/EV-304 demonstrated statistically significant improvements in event-free and overall survival with perioperative pembrolizumab plus enfortumab vedotin-ejfv compared with neoadjuvant gemcitabine plus cisplatin.